1. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database 
Marco Bandini, Elio Mazzone, Felix Preisser, Sebastiano Nazzani, Emanuele Zaffuto, Michele Marchioni, Zhe Tian, Raisa S. Pompe, Derya Tilki, Markus Graefen, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti, Pierre Karakiewicz 
European Urology Oncology 
Volume 1, Issue 4, Pages (September 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Age-adjusted temporal trends during 2004–2014 for newly diagnosed metastatic prostate cancer per population.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Annual trends (LOWESS) for (A) baseline prostate-specific antigen (PSA; <50, 50–98, and >98ng/ml), (B) biopsy Gleason score (GS ≤6, GS 7, GS 8–10), (C) clinical T stage (cT1, cT2, and cT3–4), (D) metastasis substage (M1a, M1b, and M1c), and (E) age at diagnosis.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions